- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MUSCLEPHARM Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ELI LILLY | 911,80 | +0,39 % | Abivax im Höhenrausch: Schlägt Eli Lilly jetzt zu? | An den Märkten herrscht weitgehend vorweihnachtliche Ruhe. An der Pariser Börse sorgt aber Abivax mit einem Kurssprung von rund acht Prozent für Aufsehen. Hintergrund sind Übernahmegerüchte: Ein US-Pharmariese... ► Artikel lesen | |
| TEVA | 26,500 | +0,76 % | Teva Pharmaceutical Industries Ltd: S&P Global Ratings Upgrades Teva to 'BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive | The two updates underscore Teva's strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 14,100 | -2,76 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University | Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-enabling... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 23,580 | 0,00 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
UBS Global Healthcare Conference
Fireside Chat: Monday, November 10... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | BLUM HOLDINGS, INC. - 8-K, Current Report | ||
| OTSUKA HOLDINGS | 49,600 | +2,90 % | Otsuka Initiates Global Phase 3 Trial Of Repinatrabit For Phenylketonuria | TOKYO (dpa-AFX) - Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced the launch of a global Phase 3 clinical trial for... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 82,12 | -3,00 % | Cantor Fitzgerald bestätigt "Overweight" für Bright Minds Biosciences und sieht Potenzial in Hauptwirkstoff BMB-101 | ||
| BIOHAVEN | 11,145 | +3,96 % | Biohaven Ltd.: Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder | NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization... ► Artikel lesen | |
| HARROW | 50,09 | -0,14 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,990 | +0,34 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| UNIVERSE PHARMACEUTICALS | 5,620 | +31,00 % | Universe Pharmaceuticals INC - 6-K, Report of foreign issuer | ||
| ETON PHARMACEUTICALS | 16,830 | -0,94 % | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) | - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 12,950 | -0,23 % | Astria Therapeutics, Inc. - 8-K, Current Report | ||
| MILESTONE PHARMACEUTICALS | 2,080 | +0,48 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,990 | +20,61 % | Inhibikase: H.C. Wainwright startet Coverage mit "Buy" und 385 % Kurspotenzial |
MUSCLEPHARM CORPORATION gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MUSCLEPHARM CORPORATION finden Sie auf Wallstreet Online.